Miles Cunningham, MD
Psychiatry · Belmont, MANPI 1922014331
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $50,057 of the $75,189 with a category attached, or 66.6%. FHC, Inc. accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $8354.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- FHC, Inc.$75K
- Sunovion Pharmaceuticals Inc.$104
Across 1 payment — averaging $21,816 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- FHC, Inc.$22K
Across 6 payments — averaging $30,394 each. An ownership or investment interest held by the physician or an immediate family member.
- FHC, Inc.$182K
What the payments were for
- Food & beverage$1040%
- Ownership interest$50,05767%
- Other$25,02933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| FHC, Inc. | 3 | $75,086 |
| Sunovion Pharmaceuticals Inc. | 6 | $104 |
How this compares
$75,189 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 14 | $12,586 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $736 |
| Diazepam | 14 | $9 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Belmont
- Robert AlexanderBelmont$170K
- Srinivasan PillayBelmont$51K
- David RosmarinBelmont$22K
- Ipsit VahiaBelmont$22K
- Dost OngurBelmont$17K
- Ann ShinnBelmont$14K
- James HudsonBelmont$11K
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.